Search for: "Du Pont v. Du Pont"
Results 481 - 500
of 568
Sorted by Relevance
|
Sort by Date
17 May 2007, 5:04 am
In Rita Abraham and Jesco Imports, Inc. v. [read post]
14 Feb 2007, 7:10 pm
The Wet Seal, Inc. v. [read post]
25 Mar 2009, 3:00 am
Wal-Mart Stores, Inc. v. [read post]
6 Apr 2011, 12:18 am
Laboratorios Rubió (EPLAW) Gemzar (Gemcitabine) – US: ITC: Target date of 23 July 2012 set in Certain Gemcitabine (ITC 337 Law Blog) Intuniv (Guanfacine) – US: Shire files patent infringement complaint based on Mylan’s ANDA filing (Patent Docs) Isentress (Raltegravir) – India: Cipla files for compulsory license against Merck’s Isentress (Spicy IP) Losartan, HCTZ – France: Cour d’appel confirms combination products infringe mono-SPCs and sets… [read post]
5 May 2010, 8:22 am
Apr. 9, 2010). http://tinyurl.com/2a46d58 E.I. du Pont de Nemours & Co. v. [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
28 Jun 2018, 1:42 pm
In E.I. du Pont de Nemours v. [read post]
27 Sep 2019, 12:59 pm
Cir. 2002), where the Federal Circuit held that the Board erred since it did not consider the intent-to-use application and cited registrations as evidence under the second du Pont factor. [read post]
18 May 2011, 12:33 am
Du Pont (EPLAW) Opana (Oxymorphone) – US: CAFC: important decision controlling BPAI obviousness holdings: In re Kao (Patently-O) (PharmaPatents) Silenor (Doxepin) – US: Somaxon sues Actavis over application to market generic Silenor (GenericsWeb) Tanakan (Ginko Biloba) – France: Mylan ordered to pay €17M to Ipsen for unfair competition by marketing Vitalogink to pharmacists as an “equivalent” to Tanakan (EPLAW) Valcyte (Valganciclovir) – US:… [read post]
17 May 2011, 8:12 am
” Further murking up the waters are cases such as a Du Pont case which states that considered art extends to all patents classified in the searched classes. [read post]
10 Jan 2011, 2:09 pm
" E.I. du Pont de Nemours & Co. v. [read post]
28 Dec 2011, 3:00 am
Helvering, 290 U.S. 111, 114 (1933) (“decisive distinctions [between capital and ordinary expenditures] are those of degree and not of kind”); Deputy v. du Pont, 308 U.S. 488, 496 (1940) (each case “turns on its special facts”). [read post]
25 Apr 2011, 1:23 pm
E.I. du Pont de Nemours and Company (Click here for details)Waste Information & Management Services, Inc. [read post]
6 Oct 2014, 4:28 am
McDonald’s Corp. v. [read post]
17 Sep 2018, 10:27 am
I. du Pont de Nemours and Company and ArcherDaniels-MidlandCompany (collectively, “DuPont”) appealfrom an inter partes review (“IPR”) decision of the UnitedStates Patent and Trademark Office Patent Trial andAppeal Board (the “Board”). [read post]
17 May 2021, 4:17 am
The Du Pont Merck 1997 BIP 90 (CP) One of the few cases relating to compulsory licenses in South Africa is the Atomic Energy case. [read post]
1 Mar 2021, 3:51 am
Du Pont de Nemours & Co., 584 A2d 490, 509 [Del Ch 1990], the Court rejected a valuation analysis that compared adjusted book value to market price as “akin to comparing apples to oranges. [read post]
13 Jun 2012, 11:45 am
In E.I. du Pont de Nemours v. [read post]
27 Sep 2010, 3:30 am
Toro Co. v. [read post]
